nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.12	0.363	CbGbCtD
Epoprostenol—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.12	0.363	CbGbCtD
Epoprostenol—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0913	0.275	CbGbCtD
Epoprostenol—PTGIR—pulmonary artery—chronic obstructive pulmonary disease	0.0469	0.403	CbGeAlD
Epoprostenol—PTGIS—respiratory system—chronic obstructive pulmonary disease	0.0137	0.118	CbGeAlD
Epoprostenol—PTGIS—connective tissue—chronic obstructive pulmonary disease	0.0121	0.104	CbGeAlD
Epoprostenol—PTGIS—smooth muscle tissue—chronic obstructive pulmonary disease	0.0111	0.095	CbGeAlD
Epoprostenol—PTGIR—respiratory system—chronic obstructive pulmonary disease	0.00788	0.0677	CbGeAlD
Epoprostenol—PTGIS—lung—chronic obstructive pulmonary disease	0.00729	0.0626	CbGeAlD
Epoprostenol—PTGIR—connective tissue—chronic obstructive pulmonary disease	0.00694	0.0596	CbGeAlD
Epoprostenol—PTGIR—smooth muscle tissue—chronic obstructive pulmonary disease	0.00635	0.0545	CbGeAlD
Epoprostenol—PTGIR—lung—chronic obstructive pulmonary disease	0.00419	0.036	CbGeAlD
Epoprostenol—PTGIR—Hemostasis—RAPGEF3—chronic obstructive pulmonary disease	0.000879	0.00506	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000857	0.00493	CbGpPWpGaD
Epoprostenol—CYP2C9—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000825	0.00475	CbGpPWpGaD
Epoprostenol—PTGIR—Platelet homeostasis—NOS3—chronic obstructive pulmonary disease	0.000818	0.00471	CbGpPWpGaD
Epoprostenol—CYP2C9—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000794	0.00457	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000788	0.00454	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000788	0.00454	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—SERPINE1—chronic obstructive pulmonary disease	0.000778	0.00448	CbGpPWpGaD
Epoprostenol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000743	0.00428	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—APIP—chronic obstructive pulmonary disease	0.000735	0.00423	CbGpPWpGaD
Epoprostenol—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00073	0.00193	CcSEcCtD
Epoprostenol—Cough—Montelukast—chronic obstructive pulmonary disease	0.000721	0.00191	CcSEcCtD
Epoprostenol—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000719	0.0019	CcSEcCtD
Epoprostenol—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000718	0.0019	CcSEcCtD
Epoprostenol—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000718	0.0019	CcSEcCtD
Epoprostenol—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000718	0.0019	CcSEcCtD
Epoprostenol—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000718	0.0019	CcSEcCtD
Epoprostenol—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000718	0.0019	CcSEcCtD
Epoprostenol—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000718	0.0019	CcSEcCtD
Epoprostenol—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000716	0.00189	CcSEcCtD
Epoprostenol—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000716	0.00189	CcSEcCtD
Epoprostenol—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000715	0.00189	CcSEcCtD
Epoprostenol—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000715	0.00189	CcSEcCtD
Epoprostenol—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000714	0.00189	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000713	0.00189	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000713	0.00189	CcSEcCtD
Epoprostenol—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000704	0.00186	CcSEcCtD
Epoprostenol—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000704	0.00186	CcSEcCtD
Epoprostenol—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000704	0.00186	CcSEcCtD
Epoprostenol—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000702	0.00186	CcSEcCtD
Epoprostenol—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000702	0.00186	CcSEcCtD
Epoprostenol—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000701	0.00186	CcSEcCtD
Epoprostenol—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.0007	0.00185	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000699	0.00185	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000698	0.00185	CcSEcCtD
Epoprostenol—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000695	0.00184	CcSEcCtD
Epoprostenol—PTGIR—Thromboxane A2 receptor signaling—EGFR—chronic obstructive pulmonary disease	0.000692	0.00398	CbGpPWpGaD
Epoprostenol—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000689	0.00182	CcSEcCtD
Epoprostenol—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000689	0.00182	CcSEcCtD
Epoprostenol—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000689	0.00182	CcSEcCtD
Epoprostenol—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000689	0.00182	CcSEcCtD
Epoprostenol—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000684	0.00181	CcSEcCtD
Epoprostenol—Infection—Formoterol—chronic obstructive pulmonary disease	0.000684	0.00181	CcSEcCtD
Epoprostenol—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000678	0.0018	CcSEcCtD
Epoprostenol—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000678	0.0018	CcSEcCtD
Epoprostenol—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000678	0.0018	CcSEcCtD
Epoprostenol—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000678	0.00179	CcSEcCtD
Epoprostenol—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	0.000676	0.00179	CcSEcCtD
Epoprostenol—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000676	0.00179	CcSEcCtD
Epoprostenol—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000675	0.00179	CcSEcCtD
Epoprostenol—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000675	0.00179	CcSEcCtD
Epoprostenol—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000674	0.00179	CcSEcCtD
Epoprostenol—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000674	0.00179	CcSEcCtD
Epoprostenol—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000674	0.00179	CcSEcCtD
Epoprostenol—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000672	0.00178	CcSEcCtD
Epoprostenol—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000672	0.00178	CcSEcCtD
Epoprostenol—Infection—Montelukast—chronic obstructive pulmonary disease	0.00067	0.00177	CcSEcCtD
Epoprostenol—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000669	0.00177	CcSEcCtD
Epoprostenol—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000669	0.00177	CcSEcCtD
Epoprostenol—PTGER1—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000667	0.00384	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000667	0.00176	CcSEcCtD
Epoprostenol—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000663	0.00176	CcSEcCtD
Epoprostenol—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.000662	0.00175	CcSEcCtD
Epoprostenol—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000661	0.00175	CcSEcCtD
Epoprostenol—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.00066	0.00175	CcSEcCtD
Epoprostenol—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.00066	0.00175	CcSEcCtD
Epoprostenol—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000659	0.00174	CcSEcCtD
Epoprostenol—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000655	0.00173	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000652	0.00375	CbGpPWpGaD
Epoprostenol—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.00065	0.00172	CcSEcCtD
Epoprostenol—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.00065	0.00172	CcSEcCtD
Epoprostenol—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000646	0.00171	CcSEcCtD
Epoprostenol—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000643	0.0017	CcSEcCtD
Epoprostenol—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000643	0.0017	CcSEcCtD
Epoprostenol—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00064	0.00169	CcSEcCtD
Epoprostenol—Shock—Salbutamol—chronic obstructive pulmonary disease	0.00064	0.00169	CcSEcCtD
Epoprostenol—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000638	0.00169	CcSEcCtD
Epoprostenol—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000635	0.00168	CcSEcCtD
Epoprostenol—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000632	0.00167	CcSEcCtD
Epoprostenol—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000629	0.00166	CcSEcCtD
Epoprostenol—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000629	0.00166	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000627	0.00166	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000627	0.00166	CcSEcCtD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000627	0.00361	CbGpPWpGaD
Epoprostenol—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000623	0.00165	CcSEcCtD
Epoprostenol—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000623	0.00165	CcSEcCtD
Epoprostenol—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.00062	0.00164	CcSEcCtD
Epoprostenol—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000619	0.00164	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000614	0.00163	CcSEcCtD
Epoprostenol—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000614	0.00163	CcSEcCtD
Epoprostenol—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000614	0.00163	CcSEcCtD
Epoprostenol—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000612	0.00162	CcSEcCtD
Epoprostenol—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000612	0.00162	CcSEcCtD
Epoprostenol—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.00061	0.00161	CcSEcCtD
Epoprostenol—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000608	0.00161	CcSEcCtD
Epoprostenol—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000606	0.0016	CcSEcCtD
Epoprostenol—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000606	0.0016	CcSEcCtD
Epoprostenol—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000606	0.0016	CcSEcCtD
Epoprostenol—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000604	0.0016	CcSEcCtD
Epoprostenol—PTGIR—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.0006	0.00345	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.0006	0.00345	CbGpPWpGaD
Epoprostenol—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.0006	0.00159	CcSEcCtD
Epoprostenol—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000598	0.00158	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000597	0.00343	CbGpPWpGaD
Epoprostenol—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000594	0.00157	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000594	0.00157	CcSEcCtD
Epoprostenol—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000594	0.00157	CcSEcCtD
Epoprostenol—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000594	0.00157	CcSEcCtD
Epoprostenol—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000594	0.00157	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000592	0.00157	CcSEcCtD
Epoprostenol—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000589	0.00156	CcSEcCtD
Epoprostenol—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000589	0.00156	CcSEcCtD
Epoprostenol—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000589	0.00156	CcSEcCtD
Epoprostenol—Pain—Formoterol—chronic obstructive pulmonary disease	0.000589	0.00156	CcSEcCtD
Epoprostenol—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000588	0.00156	CcSEcCtD
Epoprostenol—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000584	0.00155	CcSEcCtD
Epoprostenol—PTGER1—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000584	0.00336	CbGpPWpGaD
Epoprostenol—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000582	0.00154	CcSEcCtD
Epoprostenol—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000581	0.00154	CcSEcCtD
Epoprostenol—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.00058	0.00153	CcSEcCtD
Epoprostenol—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000578	0.00153	CcSEcCtD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000577	0.00332	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000577	0.00332	CbGpPWpGaD
Epoprostenol—Pain—Montelukast—chronic obstructive pulmonary disease	0.000577	0.00153	CcSEcCtD
Epoprostenol—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000576	0.00153	CcSEcCtD
Epoprostenol—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000575	0.00152	CcSEcCtD
Epoprostenol—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000573	0.00152	CcSEcCtD
Epoprostenol—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000572	0.00152	CcSEcCtD
Epoprostenol—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00057	0.00151	CcSEcCtD
Epoprostenol—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00057	0.00151	CcSEcCtD
Epoprostenol—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000567	0.0015	CcSEcCtD
Epoprostenol—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000565	0.0015	CcSEcCtD
Epoprostenol—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000565	0.0015	CcSEcCtD
Epoprostenol—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000564	0.00149	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000563	0.00149	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000563	0.00149	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000561	0.00149	CcSEcCtD
Epoprostenol—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000561	0.00148	CcSEcCtD
Epoprostenol—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000556	0.00147	CcSEcCtD
Epoprostenol—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000556	0.00147	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000551	0.00146	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	0.000548	0.00316	CbGpPWpGaD
Epoprostenol—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000547	0.00145	CcSEcCtD
Epoprostenol—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000547	0.00145	CcSEcCtD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000546	0.00314	CbGpPWpGaD
Epoprostenol—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000544	0.00144	CcSEcCtD
Epoprostenol—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000544	0.00144	CcSEcCtD
Epoprostenol—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000544	0.00144	CcSEcCtD
Epoprostenol—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000544	0.00144	CcSEcCtD
Epoprostenol—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000542	0.00144	CcSEcCtD
Epoprostenol—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000538	0.00142	CcSEcCtD
Epoprostenol—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000537	0.00142	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000537	0.00309	CbGpPWpGaD
Epoprostenol—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000537	0.00142	CcSEcCtD
Epoprostenol—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000536	0.00142	CcSEcCtD
Epoprostenol—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000534	0.00141	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000534	0.00307	CbGpPWpGaD
Epoprostenol—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000534	0.00141	CcSEcCtD
Epoprostenol—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000533	0.00141	CcSEcCtD
Epoprostenol—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000533	0.00141	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000532	0.00141	CcSEcCtD
Epoprostenol—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000528	0.0014	CcSEcCtD
Epoprostenol—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000525	0.00139	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	0.000524	0.00302	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000522	0.003	CbGpPWpGaD
Epoprostenol—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000516	0.00137	CcSEcCtD
Epoprostenol—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000514	0.00136	CcSEcCtD
Epoprostenol—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000514	0.00136	CcSEcCtD
Epoprostenol—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000507	0.00134	CcSEcCtD
Epoprostenol—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000507	0.00134	CcSEcCtD
Epoprostenol—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000507	0.00134	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	0.000505	0.0029	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000497	0.00132	CcSEcCtD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000495	0.00285	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000495	0.00285	CbGpPWpGaD
Epoprostenol—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000494	0.00131	CcSEcCtD
Epoprostenol—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000494	0.00131	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000492	0.00283	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000492	0.00283	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—TGFB1—chronic obstructive pulmonary disease	0.000491	0.00283	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.00049	0.00282	CbGpPWpGaD
Epoprostenol—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000487	0.00129	CcSEcCtD
Epoprostenol—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000487	0.00129	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000487	0.0028	CbGpPWpGaD
Epoprostenol—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000484	0.00128	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	0.000483	0.00278	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000483	0.00278	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.00048	0.00276	CbGpPWpGaD
Epoprostenol—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.00048	0.00127	CcSEcCtD
Epoprostenol—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000479	0.00127	CcSEcCtD
Epoprostenol—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000477	0.00126	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—TGFB2—chronic obstructive pulmonary disease	0.000476	0.00274	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GC—chronic obstructive pulmonary disease	0.000474	0.00272	CbGpPWpGaD
Epoprostenol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000472	0.00271	CbGpPWpGaD
Epoprostenol—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000471	0.00125	CcSEcCtD
Epoprostenol—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000471	0.00125	CcSEcCtD
Epoprostenol—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000466	0.00123	CcSEcCtD
Epoprostenol—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000466	0.00268	CbGpPWpGaD
Epoprostenol—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000461	0.00122	CcSEcCtD
Epoprostenol—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.00046	0.00122	CcSEcCtD
Epoprostenol—PTGIS—Adipogenesis—TNF—chronic obstructive pulmonary disease	0.000459	0.00264	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000457	0.00263	CbGpPWpGaD
Epoprostenol—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000455	0.00121	CcSEcCtD
Epoprostenol—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000455	0.00121	CcSEcCtD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000451	0.0026	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000451	0.0026	CbGpPWpGaD
Epoprostenol—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000446	0.00118	CcSEcCtD
Epoprostenol—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000445	0.00118	CcSEcCtD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000442	0.00254	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000442	0.00254	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.00044	0.00253	CbGpPWpGaD
Epoprostenol—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000438	0.00116	CcSEcCtD
Epoprostenol—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000438	0.00116	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—TGFB2—chronic obstructive pulmonary disease	0.000438	0.00252	CbGpPWpGaD
Epoprostenol—Rash—Formoterol—chronic obstructive pulmonary disease	0.000434	0.00115	CcSEcCtD
Epoprostenol—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000434	0.00115	CcSEcCtD
Epoprostenol—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000434	0.00115	CcSEcCtD
Epoprostenol—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000434	0.00115	CcSEcCtD
Epoprostenol—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000431	0.00114	CcSEcCtD
Epoprostenol—Headache—Formoterol—chronic obstructive pulmonary disease	0.000431	0.00114	CcSEcCtD
Epoprostenol—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000431	0.00114	CcSEcCtD
Epoprostenol—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00043	0.00114	CcSEcCtD
Epoprostenol—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000429	0.00114	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—HDAC2—chronic obstructive pulmonary disease	0.000427	0.00245	CbGpPWpGaD
Epoprostenol—Rash—Montelukast—chronic obstructive pulmonary disease	0.000425	0.00113	CcSEcCtD
Epoprostenol—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000425	0.00112	CcSEcCtD
Epoprostenol—Depression—Prednisone—chronic obstructive pulmonary disease	0.000424	0.00112	CcSEcCtD
Epoprostenol—Headache—Montelukast—chronic obstructive pulmonary disease	0.000423	0.00112	CcSEcCtD
Epoprostenol—PTGER1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000421	0.00242	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000421	0.00242	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.00042	0.00242	CbGpPWpGaD
Epoprostenol—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000419	0.00111	CcSEcCtD
Epoprostenol—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000416	0.0011	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000415	0.00239	CbGpPWpGaD
Epoprostenol—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000413	0.00109	CcSEcCtD
Epoprostenol—Rash—Salbutamol—chronic obstructive pulmonary disease	0.00041	0.00109	CcSEcCtD
Epoprostenol—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.00041	0.00108	CcSEcCtD
Epoprostenol—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.00041	0.00108	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000409	0.00235	CbGpPWpGaD
Epoprostenol—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000409	0.00108	CcSEcCtD
Epoprostenol—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000409	0.00108	CcSEcCtD
Epoprostenol—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000407	0.00108	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	0.000405	0.00233	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—ALB—chronic obstructive pulmonary disease	0.000404	0.00233	CbGpPWpGaD
Epoprostenol—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000402	0.00106	CcSEcCtD
Epoprostenol—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000401	0.00106	CcSEcCtD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000397	0.00228	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—HDAC2—chronic obstructive pulmonary disease	0.000393	0.00226	CbGpPWpGaD
Epoprostenol—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000388	0.00103	CcSEcCtD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000387	0.00222	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000387	0.00222	CbGpPWpGaD
Epoprostenol—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000386	0.00102	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—PLAUR—chronic obstructive pulmonary disease	0.000385	0.00221	CbGpPWpGaD
Epoprostenol—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000383	0.00101	CcSEcCtD
Epoprostenol—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000382	0.0022	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000382	0.0022	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000382	0.0022	CbGpPWpGaD
Epoprostenol—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000381	0.00101	CcSEcCtD
Epoprostenol—PTGIR—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000377	0.00217	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000377	0.00217	CbGpPWpGaD
Epoprostenol—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000375	0.000992	CcSEcCtD
Epoprostenol—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000373	0.000987	CcSEcCtD
Epoprostenol—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000373	0.000987	CcSEcCtD
Epoprostenol—PTGIS—Adipogenesis—IL6—chronic obstructive pulmonary disease	0.00037	0.00213	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000369	0.00212	CbGpPWpGaD
Epoprostenol—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000367	0.000971	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000366	0.0021	CbGpPWpGaD
Epoprostenol—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000364	0.000963	CcSEcCtD
Epoprostenol—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.00036	0.000954	CcSEcCtD
Epoprostenol—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000354	0.000937	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—PLAUR—chronic obstructive pulmonary disease	0.000354	0.00204	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	0.000351	0.00202	CbGpPWpGaD
Epoprostenol—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000346	0.000916	CcSEcCtD
Epoprostenol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000343	0.00197	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000339	0.00195	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000339	0.00195	CbGpPWpGaD
Epoprostenol—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000338	0.00195	CbGpPWpGaD
Epoprostenol—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000337	0.000893	CcSEcCtD
Epoprostenol—PTGIR—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000337	0.00194	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000337	0.00194	CbGpPWpGaD
Epoprostenol—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000335	0.000886	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000335	0.00193	CbGpPWpGaD
Epoprostenol—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000334	0.000885	CcSEcCtD
Epoprostenol—P2RY12—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	0.000326	0.00188	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000324	0.00186	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.00032	0.00184	CbGpPWpGaD
Epoprostenol—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000319	0.000844	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000308	0.00177	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000308	0.00177	CbGpPWpGaD
Epoprostenol—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000307	0.000812	CcSEcCtD
Epoprostenol—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000305	0.000808	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000298	0.00171	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000298	0.00171	CbGpPWpGaD
Epoprostenol—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000298	0.000788	CcSEcCtD
Epoprostenol—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000296	0.000784	CcSEcCtD
Epoprostenol—PTGIR—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000294	0.00169	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000294	0.00169	CbGpPWpGaD
Epoprostenol—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000292	0.000773	CcSEcCtD
Epoprostenol—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000283	0.000748	CcSEcCtD
Epoprostenol—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000283	0.000748	CcSEcCtD
Epoprostenol—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000282	0.000746	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000281	0.000743	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	0.000278	0.0016	CbGpPWpGaD
Epoprostenol—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000278	0.0016	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—MMP1—chronic obstructive pulmonary disease	0.000275	0.00158	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000275	0.000727	CcSEcCtD
Epoprostenol—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000271	0.000717	CcSEcCtD
Epoprostenol—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000271	0.000717	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—PLAU—chronic obstructive pulmonary disease	0.00027	0.00155	CbGpPWpGaD
Epoprostenol—Infection—Prednisone—chronic obstructive pulmonary disease	0.000269	0.000713	CcSEcCtD
Epoprostenol—Shock—Prednisone—chronic obstructive pulmonary disease	0.000267	0.000706	CcSEcCtD
Epoprostenol—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000266	0.000704	CcSEcCtD
Epoprostenol—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000264	0.0007	CcSEcCtD
Epoprostenol—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000263	0.000697	CcSEcCtD
Epoprostenol—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000262	0.000693	CcSEcCtD
Epoprostenol—PTGIS—Disease—HDAC2—chronic obstructive pulmonary disease	0.00026	0.00149	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.00026	0.00149	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GSTT1—chronic obstructive pulmonary disease	0.000259	0.00149	CbGpPWpGaD
Epoprostenol—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000258	0.000684	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—GCLC—chronic obstructive pulmonary disease	0.000256	0.00147	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	0.000256	0.00147	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—MMP1—chronic obstructive pulmonary disease	0.000253	0.00146	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—PLAU—chronic obstructive pulmonary disease	0.000248	0.00143	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—NOS2—chronic obstructive pulmonary disease	0.000248	0.00143	CbGpPWpGaD
Epoprostenol—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000247	0.000654	CcSEcCtD
Epoprostenol—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000247	0.000653	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000245	0.00141	CbGpPWpGaD
Epoprostenol—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000245	0.000649	CcSEcCtD
Epoprostenol—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000244	0.00141	CbGpPWpGaD
Epoprostenol—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000243	0.000644	CcSEcCtD
Epoprostenol—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000242	0.00139	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KL—chronic obstructive pulmonary disease	0.000241	0.00139	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000239	0.00137	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000239	0.00137	CbGpPWpGaD
Epoprostenol—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000239	0.000631	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	0.000238	0.00137	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	0.000236	0.00136	CbGpPWpGaD
Epoprostenol—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000236	0.000624	CcSEcCtD
Epoprostenol—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000235	0.000622	CcSEcCtD
Epoprostenol—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000235	0.000622	CcSEcCtD
Epoprostenol—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000234	0.000618	CcSEcCtD
Epoprostenol—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000234	0.000618	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—CTGF—chronic obstructive pulmonary disease	0.000233	0.00134	CbGpPWpGaD
Epoprostenol—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000232	0.000613	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000231	0.00133	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—NOS2—chronic obstructive pulmonary disease	0.000228	0.00131	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000226	0.0013	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000226	0.0013	CbGpPWpGaD
Epoprostenol—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000222	0.000587	CcSEcCtD
Epoprostenol—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000221	0.000586	CcSEcCtD
Epoprostenol—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000215	0.00057	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000215	0.00124	CbGpPWpGaD
Epoprostenol—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000214	0.000567	CcSEcCtD
Epoprostenol—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000214	0.000567	CcSEcCtD
Epoprostenol—PTGER1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000213	0.00122	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000213	0.00122	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.00021	0.00121	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	0.000209	0.0012	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—ALB—chronic obstructive pulmonary disease	0.000208	0.0012	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000207	0.00119	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000203	0.00117	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.0002	0.00115	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.0002	0.000529	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—NOS3—chronic obstructive pulmonary disease	0.000199	0.00115	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000198	0.00114	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000198	0.00114	CbGpPWpGaD
Epoprostenol—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000194	0.000515	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000193	0.00111	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000193	0.00111	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	0.000192	0.00111	CbGpPWpGaD
Epoprostenol—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000192	0.000508	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—ALB—chronic obstructive pulmonary disease	0.000192	0.0011	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.00019	0.00109	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.00019	0.00109	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000188	0.00108	CbGpPWpGaD
Epoprostenol—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000185	0.000491	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—NOS3—chronic obstructive pulmonary disease	0.000183	0.00106	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000182	0.00105	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000182	0.00105	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000182	0.00105	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000182	0.00105	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	0.000181	0.00104	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—ERBB3—chronic obstructive pulmonary disease	0.000181	0.00104	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000181	0.00104	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GSTP1—chronic obstructive pulmonary disease	0.000179	0.00103	CbGpPWpGaD
Epoprostenol—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000179	0.000474	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—HMOX1—chronic obstructive pulmonary disease	0.000177	0.00102	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000173	0.000994	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000173	0.000994	CbGpPWpGaD
Epoprostenol—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000172	0.000456	CcSEcCtD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000172	0.000989	CbGpPWpGaD
Epoprostenol—Rash—Prednisone—chronic obstructive pulmonary disease	0.000171	0.000452	CcSEcCtD
Epoprostenol—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000171	0.000452	CcSEcCtD
Epoprostenol—Headache—Prednisone—chronic obstructive pulmonary disease	0.00017	0.000449	CcSEcCtD
Epoprostenol—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000169	0.000975	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000167	0.000962	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000166	0.000957	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000166	0.000957	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GSTM1—chronic obstructive pulmonary disease	0.000165	0.000948	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000164	0.000945	CbGpPWpGaD
Epoprostenol—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000161	0.000426	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000156	0.000899	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000156	0.000896	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000154	0.000884	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000151	0.000869	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000151	0.000869	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NOS2—chronic obstructive pulmonary disease	0.000151	0.000868	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000148	0.000849	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000146	0.000838	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000145	0.000832	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—VEGFA—chronic obstructive pulmonary disease	0.000144	0.000826	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000134	0.000774	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000133	0.000766	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000133	0.000766	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—VEGFA—chronic obstructive pulmonary disease	0.000132	0.00076	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TGFB1—chronic obstructive pulmonary disease	0.000132	0.000758	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—SERPINE1—chronic obstructive pulmonary disease	0.000127	0.000731	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.000124	0.000714	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000124	0.000712	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000124	0.000712	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NOS3—chronic obstructive pulmonary disease	0.000121	0.000698	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TGFB1—chronic obstructive pulmonary disease	0.000121	0.000698	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	0.000119	0.000683	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.000114	0.000657	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.000114	0.000657	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	0.000112	0.000643	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.000111	0.000638	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—chronic obstructive pulmonary disease	0.000108	0.000624	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ALB—chronic obstructive pulmonary disease	0.000106	0.000611	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	0.000103	0.000591	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	0.000103	0.000591	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.000102	0.000587	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.000102	0.000587	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—NOS3—chronic obstructive pulmonary disease	0.000102	0.000584	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	0.000101	0.000584	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	0.000101	0.00058	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—chronic obstructive pulmonary disease	9.98e-05	0.000574	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.7e-05	0.000558	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.33e-05	0.000537	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.33e-05	0.000537	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.27e-05	0.000534	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.27e-05	0.000534	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.02e-05	0.000519	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.93e-05	0.000514	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.93e-05	0.000514	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	8.47e-05	0.000487	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.3e-05	0.000477	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.3e-05	0.000477	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TGFB1—chronic obstructive pulmonary disease	8.02e-05	0.000461	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	7.87e-05	0.000453	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EGFR—chronic obstructive pulmonary disease	7.86e-05	0.000452	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	7.8e-05	0.000449	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	7.65e-05	0.00044	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.41e-05	0.000427	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	7.11e-05	0.000409	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.08e-05	0.000407	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.82e-05	0.000393	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.82e-05	0.000393	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.75e-05	0.000389	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.51e-05	0.000375	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.51e-05	0.000375	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.22e-05	0.000358	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.22e-05	0.000358	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6—chronic obstructive pulmonary disease	6.04e-05	0.000348	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.99e-05	0.000345	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.7e-05	0.000328	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	5.67e-05	0.000326	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.51e-05	0.000317	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.51e-05	0.000317	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.42e-05	0.000312	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.24e-05	0.000302	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.24e-05	0.000302	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.99e-05	0.000287	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.99e-05	0.000287	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.87e-05	0.00028	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.48e-05	0.000258	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.48e-05	0.000258	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.47e-05	0.000257	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.38e-05	0.000252	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.18e-05	0.000241	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	4.13e-05	0.000238	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.11e-05	0.000237	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.11e-05	0.000237	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.03e-05	0.000232	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.03e-05	0.000232	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	3.85e-05	0.000222	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	3.77e-05	0.000217	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.68e-05	0.000212	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.47e-05	0.0002	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.38e-05	0.000195	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.38e-05	0.000195	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.37e-05	0.000194	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.1e-05	0.000178	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.1e-05	0.000178	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.9e-05	0.000167	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.86e-05	0.000164	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.66e-05	0.000153	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.52e-05	0.000145	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	1.72e-05	9.87e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	1.64e-05	9.44e-05	CbGpPWpGaD
